Noxopharm appoints Dr Olivier Laczka as new CEO
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Noxopharm Ltd. has appointed Dr Olivier Laczka as its new Chief Executive Officer, effective immediately, ensuring a seamless transition within the company. Dr Laczka, previously the Chief Scientific Officer, has been instrumental in developing the company's Sofra technology platform and will focus on emerging opportunities. The announcement highlights Dr Laczka's experience and vision as key to steering Noxopharm's growth and enhancing shareholder value.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Noxopharm
- Resignation of Chief Executive Officer
- Appendix 4D and FY2026 Half Year Financial Report
- R&D rebate strengthens cash position
- At-the-Market (ATM) agreement with Acuity Capital
- Sofra breakthrough science publish in major medical journal
Later from Noxopharm
- Positive SOF-SKN dosing data shows prolonged skin retention
- March 2026 Quarterly Activities Report and Appendix 4C
- Innovative collaboration further expands Sofra platform
- New data shows SOF-SKN active ingredient efficacy
- Noxopharm progresses US regulatory strategy
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm